Involvement of proteinase activated receptor-2 in the vascular response to sphingosine 1-phosphate

Clin Sci (Lond). 2014 Apr;126(8):545-56. doi: 10.1042/CS20130272.

Abstract

S1P (sphingosine 1-phosphate) represents one of the key latest additions to the list of vasoactive substances that modulate vascular tone. PAR-2 (proteinase activated receptor-2) has been shown to be involved in cardiovascular function. In the present study, we investigated the involvement of PAR-2 in S1P-induced effect on vascular tone. The present study has been performed by using isolated mouse aortas. Both S1P and PAR-2 agonists induced endothelium-dependent vasorelaxation. L-NAME (N(G)-nitro-L-arginine methyl ester) and wortmannin abrogated the S1P-induced vasorelaxatioin, while significantly inhibiting the PAR-2-mediated effect. Either ENMD1068, a PAR-2 antagonist, or gabexate, a serine protease inhibitor, significantly inhibited S1P-induced vasorelaxation. Aortic tissues harvested from mice overexpressing PAR-2 displayed a significant increase in vascular response to S1P as opposed to PAR-2-null mice. Immunoprecipitation and immunofluorescence studies demonstrated that S1P(1) interacted with PAR-2 and co-localized with PAR-2 on the vascular endothelial surface. Furthermore, S1P administration to vascular tissues triggered PAR-2 mobilization from the plasma membrane to the perinuclear area; S1P-induced translocation of PAR-2 was abrogated when aortic rings were pre-treated with ENMD1068 or when caveolae dysfunction occurred. Similarly, experiments performed in cultured endothelial cells (human umbilical vein endothelial cells) showed a co-localization of S1P(1) and PAR2, as well as the ability of S1P to induce PAR-2 trafficking. Our results suggest that S1P induces endothelium-dependent vasorelaxation mainly through S1P(1) and involves PAR-2 transactivation.

MeSH terms

  • Androstadienes
  • Animals
  • Aorta / drug effects*
  • Aorta / metabolism
  • Aorta / physiology
  • Blotting, Western
  • Cells, Cultured
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / metabolism
  • Endothelium, Vascular / physiology
  • Gabexate / pharmacology
  • Human Umbilical Vein Endothelial Cells / drug effects
  • Human Umbilical Vein Endothelial Cells / metabolism
  • Humans
  • In Vitro Techniques
  • Lysophospholipids / pharmacology*
  • Male
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Nitric Oxide Synthase / metabolism
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperazines / pharmacology
  • Protein Transport / drug effects
  • Receptor, PAR-2 / antagonists & inhibitors
  • Receptor, PAR-2 / genetics
  • Receptor, PAR-2 / metabolism*
  • Receptors, Lysosphingolipid / metabolism
  • Serine Proteinase Inhibitors / pharmacology
  • Sphingosine / analogs & derivatives*
  • Sphingosine / pharmacology
  • Vasodilation / drug effects*
  • Vasodilation / genetics
  • Vasodilation / physiology
  • Wortmannin

Substances

  • 1-3-methylbutyryl-N4-6-aminohexanoyl-piperazine
  • Androstadienes
  • Lysophospholipids
  • Phosphoinositide-3 Kinase Inhibitors
  • Piperazines
  • Receptor, PAR-2
  • Receptors, Lysosphingolipid
  • Serine Proteinase Inhibitors
  • sphingosine 1-phosphate
  • Gabexate
  • Nitric Oxide Synthase
  • Sphingosine
  • NG-Nitroarginine Methyl Ester
  • Wortmannin